Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • European Academy of Allergy and Clinical Immunology

Comprehensive world atlas of allergies

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
  • 5 minute read

More than 300 physicians and researchers from 40 countries met in Copenhagen from June 7-11, 2014, at the Congress of the European Academy of Allergy and Clinical Immunology. In addition to educational activities and the presentation of research results, the “Global Atlas of Allergy”, a comprehensive document on the worldwide significance of allergic diseases, was also presented at the congress.

(ee) Allergic diseases have become a true epidemic: In some countries, more than half of the population is already sensitized. Therefore, allergies are nowadays a worldwide problem of general public health. The European Academy of Allergy and Clinical Immunology (EAACI) called on all leading institutions worldwide to create an Allergy World Atlas. The document was launched during the EAACI 2014 Annual Congress (Fig. 1) . Written by the 170 key opinion leaders, the atlas covers all aspects of allergic diseases, from genetic predispositions, mechanisms, risk factors and epidemiology to diagnosis, treatment and prevention. It introduces the new concept of a comprehensive global strategy against the epidemic occurrence of allergies, involving coordinated actions by various institutions.

The document highlights the difficulties in dealing with allergic diseases. Many developing countries are particularly affected by these problems due to inadequate medical care, heterogeneous populations, and the lack of continuing education programs for medical providers and patients. In addition, the World Health Organization’s list of mandatory medications includes only a few drugs for the treatment of allergic diseases, and allergen immunotherapy (the only intervention option that alters the natural course of allergies) is listed as having limited access. In addition, the need for optimized continuing education about allergies and their treatment is emphasized. The editors are also from Switzerland (Cezmi A. Akdis, Swiss Institute for Allergy and Asthma Research, University of Zurich, and Christine Kühne, Center for Allergy and Asthma Research, Davos), among others. The World Atlas is available for download as a PDF document from the EAACI website: www.eaaci.org/globalatlas/GlobalAtlasAllergy.pdf.

Smoking parents – allergic children

In a Swedish study presented at the EAACI Congress, the authors investigated the association between children’s pre- and postnatal passive smoking and their risk of allergic disease [1]. 4090 children were followed up during 16 years. During this time, parents were repeatedly asked about their smoking habits and lifestyle factors, as well as allergic symptoms in the children. Children exposed to tobacco smoke in utero were at increased risk of developing asthma by 16 years of age (OR: 1.45, 95% CI: 1.15-1.83); their risk of allergic rhinitis or atopic dermatitis was not increased. Children exposed to secondhand smoke during childhood increased the risk of asthma (OR: 1.23; 95% CI: 1.01-1.51), rhinitis (OR: 1.18; 95% CI: 1.01-1.39), and eczema (OR: 1.26; 95% CI: 1.09-1.45). This showed a dose-dependent pattern. The risk of asthma and rhinitis was increased, especially in early childhood, and the risk of atopic dermatitis was increased in older children.

Ragweed artemisiifolia: new allergen

Allergies to Ambrosia artemisiifolia pollen are spreading rapidly in Central Europe and North America. So far, Amb-a-1 was the only identified allergen. A French research group has now discovered a new allergen (Amb-a-11) [2]. 54% of the ragweed allergy sufferers tested had formed IgE against this allergen. Molecular remodeling revealed strong structural homology with cysteine proteases known to be allergens, e.g., the house dust mite allergen Der-p-1. The allergen has been officially registered as Amb-a-11 by WHO and the International Union of Immunological Societies(WHO/IUIS)(www.allergen.org). The authors suggest that Amb-a-11 has great diagnostic and therapeutic value. 

Children with asthma: reduction of lung function in the first three years of life

The increased airway resistance in children with asthma appears to develop before school age. In-depth knowledge of when lung function deteriorates is essential to develop preventive measures. But because it is difficult to measure lung function in preschool children, little is known about it. A prospective study from Copenhagen included 411 children at high risk for allergic disease [3]. Between the ages of three and seven, these children underwent body pletysmography every six months. In addition, lung function at four weeks of age, tobacco smoke exposure (hair test), and any sensitization were recorded and tested.

Risk factors for increased airway resistance were male sex, high levels of nicotine in hair, and ORMDL3 and FLG gene variants. No significant association was found with sensitization or atopic dermatitis. Children who had asthma by the age of seven had increased airway resistance by the age of three, which did not progress in subsequent years. These results indicate that in children with asthma, airway resistance already increases in the first three years of life – so the first three years are critical in terms of reduction in lung function.

Complementary medicine products are not always harmless

Complementary and alternative medicine (CAM) products enjoy great popularity. But the quality of the preparations is not always above reproach. A Canadian study examined products purchased from local herbal stores and pharmacies in Vancouver, Canada; Hong Kong, China; and Taipei, Taiwan [4]. Several products contained active pharmaceutical ingredients, e.g., caffeine, the dosage of which exceeded the recommendation of the national health authorities, or phenazone, which can cause numerous interactions as well as allergic reactions. One product contained active pharmaceutical ingredients that were mentioned on the packaging only in Japanese – the seller was unable to provide any information about the active ingredients and was also unable to translate the Japanese instructions. The authors of the study call for stronger regulation of CAM products, as they too – especially if they contain unknown active pharmaceutical ingredients – are at risk for interactions, side effects, overdose, and allergic reactions.

Prevention of atopy in young children

This prospective, randomized, double-blind, placebo-controlled study from the United Kingdom investigated whether oral exposure to a house dust mite allergen in early childhood reduces the risk of developing allergy [5]. 111 infants were recruited, all of whom had a high genetic risk for atopy (≥2 close relatives with asthma, allergic rhinitis, or atopic dermatitis). At the time of recruitment, prick tests were negative in the children. At 6-18 months of age, the children received an active house dust mite (HDM) allergen extract or placebo orally twice daily. They were followed up every three months. The intervention group showed a significant, clinically substantial reduction in cumulative sensitization to allergens in general. There were no differences in sensitization to HDM between the two groups. Clinical symptoms such as eczema or rhinoconjunctivitis also occurred with equal frequency in both groups. The extract was well tolerated. The authors conclude that high-dose HDM immunotherapy in early childhood is effective in preventing the development of atopy in children at high genetic risk.

Source: Congress of the European Academy of Allergy and Clinical Immunology, June 7-11, 2014, Copenhagen.

Literature:

  1. Thacher J, et al: Pre- and postnatal exposure to parental smoking and allergic disease up to adolescence. Abs. 1257.
  2. Nony E, et al: Identification and characterisation of Amb a 11, a new major allergen from the pollen of short ragweed (Ambrosia artemisiifolia). Para 13.
  3. Bonnelyke K, et al: The first 3 years of life are critical to the loss of lung function associated with asthma. Abs. 303.
  4. Wong HC: Potential adverse reaction from complementary and alternative medicine (CAM) containing pharmaceutical products purchased locally and overseas. Para. 1009.
  5. Zolkipli Z, et al: Randomised controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. Abs. 1623.

DERMATOLOGIE PRAXIS 2014; 24(4): 40-42

Autoren
  • Dr. med. Eva Ebnöther
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • Allergy
  • Ambrosia
  • Asthma
  • Atopy
  • EAACI
  • HDM
  • Immunotherapy
  • Neurodermatitis
  • Rhinitis
  • Tobacco smoke
  • World Atlas
Previous Article
  • EULAR Congress

Systemic lupus erythematosus – How to manage?

  • Congress Reports
  • Dermatology and venereology
  • RX
View Post
Next Article
  • Renal failure

A booming disease?

  • Nephrology
  • News
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.